


JNK3 inhibitor-7

Cat. No.:	HY-149279
Molecular Formula:	C ₃₂ H ₃₁ N ₇ O ₃
Molecular Weight:	561.63
Target:	JNK
Pathway:	MAPK/ERK Pathway
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	JNK3 inhibitor-7 is a potent, orally active and cross the blood-brain barrier JNK3 inhibitor with IC ₅₀ values of 53, 973, 1039 nM for JNK3, JNK2, JNK1, respectively. JNK3 inhibitor-7 shows significant neuroprotective effects. JNK3 inhibitor-7 has the potential for the research of Alzheimer's disease (AD) ^[1] .										
IC₅₀ & Target	JNK3 53 nM (IC ₅₀)	JNK2 973 nM (IC ₅₀)	JNK1 1039 nM (IC ₅₀)								
In Vitro	<p>JNK3 inhibitor-7 (compound 2h; 20 μM; 24, 48 h) increases primary rat cortex neuron cell viability when treatment with 10 μM amyloid-β₁₋₄₂^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>primary rat cortex neuron cells</td> </tr> <tr> <td>Concentration:</td> <td>20 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24, 48 h</td> </tr> <tr> <td>Result:</td> <td>Increased cell viability when treatment with 10 μM amyloid-β₁₋₄₂.</td> </tr> </table>			Cell Line:	primary rat cortex neuron cells	Concentration:	20 μM	Incubation Time:	24, 48 h	Result:	Increased cell viability when treatment with 10 μM amyloid-β ₁₋₄₂ .
Cell Line:	primary rat cortex neuron cells										
Concentration:	20 μM										
Incubation Time:	24, 48 h										
Result:	Increased cell viability when treatment with 10 μM amyloid-β ₁₋₄₂ .										
In Vivo	<p>JNK3 inhibitor-7 (30, 60 mg/kg; p.o.; daily for 4 weeks) shows significant neuroprotective effects in mice^[1].</p> <p>Pharmacokinetic Parameters of JNK3 inhibitor-7 in Sprague-Dawley rats^[1].</p> <table border="1"> <tr> <td>compound</td> <td>2h</td> </tr> <tr> <td>admin.</td> <td>PO</td> </tr> <tr> <td>dose (mg/kg)</td> <td>3</td> </tr> <tr> <td>AUC_{last} (h ng/ml)</td> <td>350.68</td> </tr> </table>			compound	2h	admin.	PO	dose (mg/kg)	3	AUC _{last} (h ng/ml)	350.68
compound	2h										
admin.	PO										
dose (mg/kg)	3										
AUC _{last} (h ng/ml)	350.68										

C₀ or C_{max} (ng/mL) 342.30

T_{max} (h) 0.39

T_{1/2} (h) 0.65

Sprague-Dawley rats, 3 mg/kg p.o.^[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 7 month-old APP/PS1 AD mice^[1]

Dosage: 30, 60 mg/kg

Administration: P.o.; daily for 4 weeks

Result: Decreased the escape time and distance traveled, a dose-dependent increased in the quadrant where the escape zone was located and the time spent.

REFERENCES

[1]. Jun J, et al. Carbamate JNK3 Inhibitors Show Promise as Effective Treatments for Alzheimer's Disease: In Vivo Studies on Mouse Models. J Med Chem. 2023 Apr 24.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA